
Immunovant IMVT
$ 21.24
3.86%
Quarterly report 2024-Q4
added 02-06-2025
Country |
![]() |
IPO year |
2019 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Dr. Peter Salzmann M.B.A., M.D. |
Employees in the company |
42 |
Shares |
138 M |
Market Cap[1] |
$ 2.93 B |
EBITDA (LTM) |
$ 324 K |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.